BXP recently completed a 113,000-rsf innovation hub in Waltham, Mass. Designed by TRIA, 103 CityPoint aims to reshape corporate culture for science and technology tenants, energizing its workforce and accelerating growth. The flexible flour-story structure provides 80 percent laboratory and office space, with 20 percent accommodating a double-height cGMP manufacturing area spanning approximately 25,000 sf.
WACKER opened the mRNA Competence Center in June of 2024 in Halle an der Saale, Germany. Representing an investment of over €100 million, the next-generation facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA). The building spans a total floor area of 79,653 sf and accommodates four new lines supported by advanced infrastructure, including 17,222 sf of glass-enclosed cleanroom space for bioprocessing under controlled conditions.
Cincinnati Children’s Hospital Medical Center began construction in June of 2024 on the Applied Gene and Cell Therapy Center in Sharonville, Ohio. The $60 million project will transform an existing structure into a catalyst for innovative clinical trials. Designed by BHDP Architecture, the 111,000-sf facility will advance the development, testing, and manufacture of new medicines and biological therapies.
Sanofi opened a 20,000-sf biomanufacturing center in May of 2024 in Toronto. Producing adult and pediatric vaccines for pertussis, diphtheria, and tetanus, the project significantly increases capacity to meet growing demand in Canada and around the world. The next-generation facility features advanced bioprocessing suites supported by highly efficient infrastructure. Commissioning is currently under way, with full operations slated to commence in mid-2025.
AstraZeneca is planning to construct a US$1.5 billion facility in Singapore for the manufacture of antibody drug conjugates (ADCs). Enabling the creation of precision cancer therapies, the project will integrate every stage of the ADC production process at commercial scale. The sustainably designed building is slated to achieve net-zero operational carbon and will leverage advanced infrastructure to achieve optimal energy performance. Completion is expected in 2029. A site for the greenfield development has yet to be determined.
Siemens Healthineers—a spinoff of Siemens that focuses exclusively on healthcare equipment, solutions, and services—has begun construction on a £250 million ($314 million) facility in the United Kingdom to research and manufacture a breakthrough sustainable design for MRI superconducting magnets that reduces the need for helium from 1,500 liters (more than 396 gallons) to a single liter (just over a quart).
Merck celebrated the beginning of construction for the $325 million Advanced Research Center in April of 2024. Located on the company's Darmstadt headquarters campus in Germany, the biopharmaceutical innovation facility will accelerate the development of novel processes and materials for the production of antibodies, recombinant proteins, and viral vectors. The flexible structure will also drive advances in pharmaceutical purification, formulation, and analytical chromatography.
Savannah River National Laboratory is constructing the Advanced Manufacturing Collaborative (AMC) on the campus of the University of South Carolina Aiken. Designed by Page and STOA Architects, the $50 million facility will enable the Department of Energy's Office of Environmental Management to engage in shared discovery with academic institutions, industry partners, and government agencies at the city, state, and federal level.
The University of Delaware broke ground in April of 2024 on the Securing American Biomanufacturing Research and Education (SABRE) Center. The $150 million facility will enhance the R&D capabilities of the adjacent National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) while driving the creation of a skilled workforce. Serving as a living laboratory for the formulation of best practices, the 70,000-sf building is envisioned as a place to scale up and mature new production methods.
FUJIFILM Diosynth Biotechnologies is constructing a $3.2 billion pharmaceutical campus in Holly Springs, N.C. Integrating sophisticated automation technologies, the multi-building development will enable large-scale cell culture manufacturing for the creation of bulk drug substances. Ground was broken in October of 2021 on the first phase, a $2 billion production center slated for completion in early 2025. A subsequent investment of $1.2 billion will establish an additional 425,000-sf plant that will begin operations in 2028.
Lonza is investing $1.2 billion to purchase a pharmaceutical manufacturing campus in Vacaville, Calif. Presently occupied by Genentech, a subsidiary of Roche, the 427,000-sf complex provides a total bioreactor capacity of approximately 330 liters. Lonza is offering employment to 750 personnel at the site, which will continue to supply its current products at a committed volume of 30 percent throughout 2025.
Siemens Mobility is planning to construct a £100 million innovation center for rail infrastructure in Chippenham. Featuring world-class R&D labs for the discovery of novel travel solutions, the digitally enabled complex will produce the next generation of signaling and control systems for the United Kingdom. Open office areas designed to support hybrid working will be accompanied by sophisticated meeting rooms and collaboration spaces.
Agratas, a subsidiary of Tata Group, will break ground in spring of 2024 on a £4 billion battery factory in the United Kingdom. Located on the Gravity Smart Campus in Bridgwater, the three-building complex will leverage highly efficient processes and technologies to produce advanced battery cells for electric vehicles. The sustainable project involves the adaptive reuse of an existing brownfield site and the creation of sophisticated renewable energy systems.
Regeneron Pharmaceuticals is planning to establish a biomedical research facility in Suffern, N.Y. The company recently invested $39 million to acquire the 235,000-sf Avon Innovation Center. Sited on 10 acres, the three-story structure originally housed chemistry labs and support spaces for the development of cosmetics, fragrances, and skincare products. HLW designed the facility, which was constructed between 2003 and 2005 by Skanska USA Building.
AstraZeneca is investing $300 million to establish a cell therapy manufacturing facility in Rockville, Md. Developed by Alexandria Real Estate Equites, the Class A+ property is located in the vibrant innovation ecosystem of the Alexandria Center for Life Science at Shady Grove. AstraZeneca has executed a 13-year lease for the entire 84,264-rsf building.
